14 Influence of zoledronic acid on bone mineral density in premenopausal women with hormone receptor positive or negative breast cancer and neoadjuvant or adjuvant chemotherapy or endocrine treatment

2010 ◽  
Vol 8 (3) ◽  
pp. 62
Author(s):  
P. Hadji ◽  
A. Kauka ◽  
M. Kalder ◽  
T. Bauer ◽  
U. Albert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Adjuvant Chemotherapy ◽  
Bone Mineral ◽  
Hormone Receptor ◽  
Premenopausal Women ◽  
Endocrine Treatment ◽  
Mineral Density ◽  
Hormone Receptor Positive

scholarly journals Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809

2011 ◽  
Vol 47 (5) ◽  
pp. 683-689 ◽  
Author(s):  
C.L. Shapiro ◽  
S. Halabi ◽  
V. Hars ◽  
L. Archer ◽  
D. Weckstein ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Adjuvant Chemotherapy ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Ovarian Failure ◽  
Mineral Density

Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study

2014 ◽  
Vol 25 (4) ◽  
pp. 1369-1378 ◽  
Author(s):  
P. Hadji ◽  
A. Kauka ◽  
M. Ziller ◽  
K. Birkholz ◽  
M. Baier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Mineral Density ◽  
Adjuvant Therapies

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

2008 ◽  
Vol 9 (9) ◽  
pp. 840-849 ◽  
Author(s):  
Michael Gnant ◽  
Brigitte Mlineritsch ◽  
Gero Luschin-Ebengreuth ◽  
Franz Kainberger ◽  
Helmut Kässmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Endocrine Therapy ◽  
Bone Mineral ◽  
Early Stage ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Mineral Density

Effect of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for breast cancer: the ProBONE II Study

2013 ◽  
Author(s):  
Peyman Hadji ◽  
Anette Kauka ◽  
Thomas Bauer ◽  
Katrin Birkholz ◽  
Monika Baier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Mineral Density ◽  
Adjuvant Therapies

Characteristics of bone mineral density at the time of diagnosis in postmenopausal breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22187-e22187
Author(s):  
H. J. Kim ◽  
E. Park ◽  
W. Lim ◽  
J. Sei ◽  
B. Koh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Mass ◽  
Cancer Patients ◽  
Bone Mineral ◽  
Hormone Receptor ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Hormone Receptor Positive

e22187 Background: Bone mass has been proposed as a marker of cumulative exposure to estrogen in women. We have studied the association between bone mass and breast cancer in postmenopausal women. Methods: We investigated the association between bone mineral density(BMD), as measured at the lumbar spine and femoral neck and the breast cancer in women age 50 or older, who were received an initial diagnosis of stage 0-III breast cancer, confirmed by pathologic assessment of breast tissue. We recruited 718 women with newly diagnosed breast cancer in a Asan Medical Center from 1, Jun. 2006 to 31, Dec. 2007. BMD was measured by lunar EXPERT-XL for breast cancer patients Results: Median age at diagnosis was 58 (range 47–82). Patients with higher BMD at lumbar spine were found to have low grade disease (p<0.005). The patients with hormone receptor positive breast tumor showed higher BMD at lumbar spine and lower serum 25(OH)D than hormone receptor negative tumor. Serum estradiol level did not show a relation to BMD. There were no significant differences between breast cancer stage and serum 25(OH)D and BMD. Conclusions: The patients who have hormone receptor positive breast cancer had higher Lumbar spine BMD and lower 25(OH)D than hormone receptor negative patients. No significant financial relationships to disclose.

Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer

2001 ◽  
Vol 19 (14) ◽  
pp. 3306-3311 ◽  
Author(s):  
Charles L. Shapiro ◽  
Judith Manola ◽  
Meryl Leboff
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Adjuvant Chemotherapy ◽  
Bone Loss ◽  
Bone Mineral ◽  
Ovarian Failure ◽  
Mineral Density ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase

PURPOSE: We sought to evaluate the effects of chemotherapy-induced ovarian failure on bone loss and markers of skeletal turnover in a prospective longitudinal study of young women with breast cancer receiving adjuvant chemotherapy. PATIENTS AND METHODS: Forty-nine premenopausal women with stage I/II breast cancers receiving adjuvant chemotherapy were evaluated within 4 weeks of starting chemotherapy (baseline), and 6 and 12 months after starting chemotherapy with dual-energy absorptiometry and markers of skeletal turnover osteocalcin and bone-specific alkaline phosphatase. Chemotherapy-induced ovarian failure was defined as a negative pregnancy test, greater than 3 months of amenorrhea, and a follicle-stimulating hormone ≥ 30 MIU/mL at the 12-month evaluation. RESULTS: Among the 35 women who were defined as having ovarian failure, highly significant bone loss was observed in the lumbar spine by 6 months and increased further at 12 months. The median percentage decrease of bone mineral density in the spine from 0 to 6 months and 6 to 12 months was −4.0 (range, −10.4 to +1.0; P = .0001) and −3.7 (range, −10.1 to 9.2; P = .0001), respectively. In contrast, there were no significant decreases in bone mineral density in the 14 patients who retained ovarian function. Serum osteocalcin and bone specific alkaline phosphatase, markers of skeletal turnover, increased significantly in the women who developed ovarian failure. CONCLUSION: Chemotherapy-induced ovarian failure causes rapid and highly significant bone loss in the spine. This may have implications for long-term breast cancer survivors who may be at higher risk for osteopenia, and subsequently osteoporosis. Women with breast cancer who develop chemotherapy-induced ovarian failure should have their bone density monitored and treatments to attenuate bone loss should be evaluated.

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

2007 ◽  
Vol 25 (7) ◽  
pp. 820-828 ◽  
Author(s):  
Michael F.X. Gnant ◽  
Brigitte Mlineritsch ◽  
Gero Luschin-Ebengreuth ◽  
Stephan Grampp ◽  
Helmut Kaessmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Endocrine Therapy ◽  
Premenopausal Women ◽  
Adjuvant Endocrine Therapy ◽  
Phase Iii ◽  
Endocrine Treatment ◽  
Mineral Density ◽  
T Score

Purpose Adjuvant therapy for breast cancer can be associated with decreased bone mineral density (BMD) that may lead to skeletal morbidity. This study examined whether zoledronic acid can prevent bone loss associated with adjuvant endocrine therapy in premenopausal patients. Patients and Methods This study is a randomized, open-label, phase III, four-arm trial comparing tamoxifen (20 mg/d orally) and goserelin (3.6 mg every 28 days subcutaneously) ± zoledronic acid (4 mg intravenously every 6 months) versus anastrozole (1 mg/d orally) and goserelin ± zoledronic acid for 3 years in premenopausal women with hormone-responsive breast cancer. In a BMD subprotocol at three trial centers, patients underwent serial BMD measurements at 0, 6, 12, 24, and 36 months. Results Four hundred one patients were included in the BMD subprotocol. Endocrine treatment without zoledronic acid led to significant (P < .001) overall bone loss after 3 years of treatment (BMD, −14.4% after 36 months; mean T score reduction, −1.4). Overall bone loss was significantly more severe in patients receiving anastrozole/goserelin (BMD, −17.3%; mean T score reduction, −2.6) compared with patients receiving tamoxifen/goserelin (BMD, −11.6%; mean T score reduction, −1.1). In contrast, BMD remained stable in zoledronic acid–treated patients (P < .0001 compared with endocrine therapy alone). No interactions with age or other risk factors were noted. Conclusion Endocrine therapy caused significant bone loss that increased with treatment duration in premenopausal women with breast cancer. Zoledronic acid 4 mg every 6 months effectively inhibited bone loss. Regular BMD measurements and initiation of concomitant bisphosphonate therapy on evidence of bone loss should be considered for patients undergoing endocrine therapy.

Sign in / Sign up

Export Citation Format

Share Document